Recently, RC001, RecoRNA’s independently developed drug candidate targeting specific neurological disease, was successfully granted for Orphan Drug Designation (ODD) by the U.S. Food and Drug Administ...

On August 18, 2023, Haoyue Capital, a leading investment firm focusing on China's healthcare industry, released its "Seventh Annual list for Outstanding Healthcare Investment". RECORNA Bio w...

The competition aimed to implement the "14th Five-Year Plan" and to follow the "Guidelines on Implementing the Women's Science and Technology Innovation Action," promoting the exec...

RECORNAs participation in this competition is a positive response to the Guangdong provincial government's efforts to thoroughly implement the spirit of the central and provincial talent work conferen...